All Regulatory Rapporteur articles in May 2022

View all stories from this issue.

  • AdobeStock_474559629
    Focus

    Procedure withdrawals within Europe: past trends, impact and communication recommendations

    2022-05-18T16:00:00Z

    When an application for a new veterinary medicinal product (VMP) is submitted through a MR/DCP, the Applicant has the option to prematurely withdraw their application in the reference member state (RMS) or in one or several of the concerned member states (CMS). This would result in a total or partial withdrawal of the procedure. The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Veterinary (CMDv) sent a questionnaire to all national competent authorities…

  • AdobeStock_226352071
    Editorial

    May 2022 Editorial: CMC acceleration is driven by a scientific revolution

    2022-05-13T14:51:00Z

    The role of CMC technical and regulatory experts is essential for ensuring continuous innovation and successful regulatory approvals

  • AdobeStock_281211016
    Article

    CMC considerations for US biosimilars development

    2022-04-18T15:18:00Z

    The US Biologics Price Competition and Innovation Act of 2009 (BPCI Act) provides an abbreviated licensure pathway for biosimilar products. This pathway brought the hope of lower cost biologics, perhaps similar to what was accomplished by generics for small molecule drugs. Twelve years have now passed since the BPCI Act and experience continues to be gained with biosimilars development… 

  • AdobeStock_244609855
    Article

    A regulatory view on the change management process for medicinal products

    2022-04-18T14:53:00Z

    An effective change control process is a critical part of good manufacturing practice (GMP), during the post-approval phase of a medicinal product’s lifecycle. This article reviews key aspects of the current EU and International Conference on Harmonisation (ICH) quality guidelines. The operational aspects of the change control process are explored and guidance is provided on how the strategic review of changes can avoid or minimise the regulatory impact.

  • adobestock_237602801_optimized
    Focus

    Regulatory Framework for Platform Technologies

    2022-04-18T14:20:00Z

    Several novel manufacturing technologies and platforms, for example, messenger ribonucleic acid (mRNA) platform, synthetic DNA (doggybone (dbDNA)) platform, have recently emerged to produce vaccines and advanced therapy medicinal products (ATMPs) for human use. However, the regulatory framework for such platform technologies is not fully developed. There is significant interest in utilising platform approaches for drug development and for the commercial production of human medicines. Thus, some form of regulatory guidance and pathway, similar to the EU platform technology master le (PTMF) system that is used in the regulatory approval of veterinary vaccines, would benefit the human vaccines industry.

  • AdobeStock_282628451-min
    Article

    Amgen’s experience of global expedited regulatory pathways in the development of sotorasib (Part 1)

    2022-04-18T13:35:00Z

    On 28 May 2021, sotorasib (LUMAKRAS™/LUMYKRAS®), a novel, first-in-class, inhibitor of the RAS GTPase family became the first drug to be approved by the US Food and Drug Administration (FDA) to target Kirsten rat sarcoma proto-oncogene (KRAS) G12C. For 40 years, this condition had been considered undruggable. Sotorasib became the first approved targeted therapy for the treatment of adult patients, with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The approval was achieved in less than three years from first in human (FIH) exposure. This case study provides regulatory insights into the global expedited pathways and special designations, which were utilised during the development and marketing application review.

  • AdobeStock_141880562
    Focus

    Gene therapy products: regulatory expectations and challenges for industry

    2022-04-18T13:20:00Z

    As the technology behind gene therapy products continues to evolve, applicants face the challenge of adapting their programmes to increasingly demanding and detailed regulation. This article provides an overview of current regulatory expectations and the challenges they may present to industry.

  • AdobeStock_405906571-min
    Focus

    Practical insights into the recent EU MDR framework

    2022-04-18T13:18:00Z

    This article focuses on the impact of the new guidance document on drug-device combination (DDC) products, in Article 117 of the European Medical Device Regulation (MDR) for pharmaceutical marketing authorisation holders (MAHs). It explores the new role of the notified body (NB) versus the MAH pertaining to the device part of the DDC, some of the pitfalls encountered by pharmaceutical MAHs and potential solutions to efficiently navigate the new framework. It also provides practical insights into key technical requirements for the product-specific quality aspects of a medical device, which are within the quality dossier of a successful EU application. The article also explores efficient global implementation within fast evolving and at times divergent, regional regulations.